

Chart 7**MAPS' Phase 2 MDMA/PTSD Studies Expenses 2008-2013 in Preparation for FDA/EMEA End-of-Phase 2 Meeting**

Study	Actual 2008-09	Actual 2009-10	2010-11	2011-12	2012-13
US MDMA/PTSD	\$194,600	\$110,000	\$23,000	\$0	\$0
US MDMA/PTSD Long-Term	\$0	\$3,939	\$10,000	\$0	\$0
US MDMA/PTSD Veterans	\$1,570	\$35,806	\$219,400	\$225,000	\$25,390
US MDMA/PTSD Veterans Long-Term	\$0	\$0	\$0	\$10,000	\$25,000
Swiss MDMA/PTSD	\$48,000	\$33,500	\$15,000	\$0	\$0
Swiss MDMA/PTSD Long-Term	\$0	\$0	\$5,000	\$0	\$0
Israel MDMA/PTSD	\$13,250	\$27,308	\$50,000	\$75,000	\$0
Israel MDMA/PTSD Long-Term	\$0	\$0	\$0	\$0	\$10,000
Canadian MDMA/PTSD	\$21,600	\$9,814	\$100,000	\$140,000	\$19,626
Canadian MDMA/PTSD Long-Term	\$0	\$0	\$0	\$5,000	\$5,000
Jordanian MDMA/PTSD	\$3,470	\$31,456	\$50,000	\$50,000	\$21,116
Jordanian MDMA/PTSD Long-Term	\$0	\$0	\$0	\$2,500	\$2,500
New US MDMA/PTSD	\$0	\$0	\$0	\$125,000	\$100,500
New US MDMA/PTSD Long-Term	\$0	\$0	\$0	\$0	\$10,000
Spain MDMA/PTSD	\$3,640	\$365	\$2,000	\$0	\$0
Associated Projects	2008-09	2009-10	2010-11	2011-12	2012-13
End-of-Phase-2 Meeting w/ FDA	\$0	\$0	\$0	\$20,000	\$50,000
MDMA Literature Review	\$3,340	\$3,256	\$3,500	\$3,500	\$3,500
MDMA Treatment Manual/NIMH grant	\$640	\$8,752	\$12,000	\$5,000	\$0
MDMA Therapist Training-Protocol	\$9,600	\$15,038	\$15,000	\$20,000	\$25,000
MDMA Research Retreats	\$7,236	\$27,067	\$0	\$25,000	\$0
Mithoefer Supervisory/PR Time	\$0	\$27,951	\$62,300	\$47,000	\$47,000
MDMA Research General	\$1,830	\$11,404	\$15,000	\$15,000	\$15,000
Clinical Research General	\$13,360	\$38,036	\$40,000	\$35,000	\$35,000
Total MDMA-Related Expenses	\$322,136	\$383,692	\$622,200	\$803,000	\$394,632

Multi-Year Projected Costs \$705,828 over past two years